Longevity & AgingPress Release

Insulin resistance in your 20s predicts heart disease risk decades later

A 35-year CARDIA analysis links young-adult insulin resistance to a 50% higher risk of heart disease events, largely through midlife metabolic syndrome.

Saturday, November 21, 2026 1 view
Published in MedPage Today
Article visualization: Insulin resistance in your 20s predicts heart disease risk decades later

Summary

Insulin resistance in young adulthood may flag future heart disease long before standard risk factors appear. In the CARDIA cohort, researchers followed more than 3,000 adults who were free of cardiovascular disease at ages 38-50. About one in four had shown insulin resistance at ages 18-30, estimated by fasting glucose and insulin (HOMA-IR at or above 2.67). Over follow-up to ages 53-65, those with early insulin resistance had a 50% higher risk of atherosclerotic cardiovascular disease events (RR 1.50, 95% CI 1.13-2.01). About 63% of that link ran through metabolic syndrome in midlife, meaning the clustering of excess body fat, high blood pressure, high glucose and abnormal lipids. This is an observational study, so it shows association, not cause. It has not shown that treating early insulin resistance prevents heart disease.

Detailed Summary

Why it matters: Heart disease develops over decades, yet risk is usually assessed only after blood pressure, cholesterol and glucose have already drifted. This analysis asks whether insulin resistance, a core metabolic mechanism of aging, shows up earlier and marks who is on a bad trajectory.

Main findings: Using the CARDIA cohort, researchers studied more than 3,000 participants who were free of atherosclerotic cardiovascular disease (ASCVD) at year 20, when they were 38-50 years old. One in four had insulin resistance at baseline (ages 18-30), defined as HOMA-IR at or above the 75th percentile (2.67) after a 12-hour fast. Through year 35 (ages 53-65), these participants had a significantly higher risk of ASCVD events (RR 1.50, 95% CI 1.13-2.01).

Key insights: Metabolic syndrome at year 20 mediated an estimated 63.4% of the association (indirect RR 1.29, 95% CI 1.13-1.48). This suggests early insulin resistance leads to later risk largely by driving a cluster of problems in adiposity, blood pressure, glucose and lipids. The authors frame insulin resistance as an early signal and metabolic syndrome as a later stage of the same trajectory.

Practical implications: The results support closer cardiometabolic monitoring in young adults with insulin resistance. Fasting insulin is not routinely measured, so this is a conversation to have with a physician, not a standard test. The study does not show that lowering insulin resistance reduces heart disease.

Caveats: The design is observational, so residual confounding is possible. HOMA-IR is an indirect estimate and may not match the gold-standard hyperinsulinemic-euglycemic clamp. The authors did not account for changes in metabolic syndrome status before or after year 20. Whether HOMA-IR improves prediction beyond routine clinical factors, and whether preventing metabolic syndrome lowers ASCVD risk, remain untested.

Key Findings

  • Young-adult insulin resistance (HOMA-IR 2.67 or higher) was linked to 50% higher ASCVD risk by ages 53-65 (RR 1.50).
  • Analysis included over 3,000 CARDIA participants free of ASCVD at ages 38-50; one in four had early insulin resistance.
  • Midlife metabolic syndrome mediated about 63.4% of the association (indirect RR 1.29, 95% CI 1.13-1.48).
  • Observational design shows association only; no evidence yet that treating early insulin resistance prevents heart disease.
  • Fasting insulin is not routinely measured, and HOMA-IR may not match the clamp gold standard.

Methodology

This is a news report from MedPage Today on a JACC: Advances analysis of the prospective CARDIA cohort (more than 3,000 participants, 35-year follow-up). The evidence is observational, with insulin resistance estimated by fasting HOMA-IR and mediation analysis for metabolic syndrome. Endpoint was ASCVD events, a clinical outcome rather than a surrogate.

Study Limitations

Observational data cannot prove causation, and residual confounding is possible. HOMA-IR is an indirect measure, and changes in metabolic syndrome around year 20 were not modeled. Check the JACC: Advances paper for cohort details, adjustment variables and whether HOMA-IR adds predictive value beyond standard factors.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: